BioMarin Pharmaceutical Inc.
BMRN
$68.32
$0.380.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 747.31M | 745.74M | 712.03M | 648.83M | 646.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 747.31M | 745.74M | 712.03M | 648.83M | 646.21M |
| Cost of Revenue | 136.14M | 188.46M | 314.25M | 330.17M | 137.93M |
| Gross Profit | 611.17M | 557.28M | 397.78M | 318.67M | 508.28M |
| SG&A Expenses | 170.78M | 253.48M | 263.03M | 225.91M | 259.51M |
| Depreciation & Amortization | 9.65M | 5.01M | 14.30M | 14.30M | 15.24M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 490.08M | 631.85M | 591.58M | 570.37M | 618.93M |
| Operating Income | 257.24M | 113.89M | 120.45M | 78.46M | 27.28M |
| Income Before Tax | 169.64M | 134.44M | 132.14M | 105.55M | 19.33M |
| Income Tax Expenses | 44.70M | 28.36M | 24.96M | 16.89M | -1.05M |
| Earnings from Continuing Operations | 124.94M | 106.08M | 107.17M | 88.66M | 20.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.94M | 106.08M | 107.17M | 88.66M | 20.38M |
| EBIT | 257.24M | 113.89M | 120.45M | 78.46M | 27.28M |
| EBITDA | 280.84M | 132.90M | 146.92M | 105.81M | 54.14M |
| EPS Basic | 0.66 | 0.56 | 0.56 | 0.47 | 0.11 |
| Normalized Basic EPS | 0.87 | 0.44 | 0.43 | 0.32 | 0.06 |
| EPS Diluted | 0.64 | 0.55 | 0.55 | 0.46 | 0.09 |
| Normalized Diluted EPS | 0.84 | 0.43 | 0.41 | 0.30 | 0.06 |
| Average Basic Shares Outstanding | 190.69M | 190.43M | 190.11M | 188.87M | 188.48M |
| Average Diluted Shares Outstanding | 196.58M | 197.15M | 200.51M | 199.26M | 191.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
